Genicular nerve radiofrequency ablation
For chronic knee pain from osteoarthritis, including after total knee arthroplasty. Conventional, cooled and pulsed techniques compared against sham, intra-articular injections and usual care.
Published studies
Open in feedRecent evidence appears first, ordered by publication date. Earlier evidence and papers without precise dates follow separately. Design categories are inferred from PubMed metadata, not evidence grades.
Showing 1 of 14 · Observational
Recent evidence · past year
-
Long-Term Pain and Functional Outcomes After Cooled Genicular Radiofrequency Ablation With or Without Adjunctive Intra-Articular Botulinum Toxin Type A in Knee Osteoarthritis.
AI summary of the abstract, unverified
- Retrospective observational comparative-effectiveness cohort of 90 patients with moderate-to-severe knee osteoarthritis, followed for 24 months.
- Compared cooled genicular radiofrequency ablation alone (n=50) with the same ablation plus intra-articular botulinum toxin type A (n=40), with a planned repeat BoNT-A injection at about 12 months in the combination group.
- Significant treatment-by-time interactions were found for NRS (ß=-0.84, 95% CI -1.21 to -0.47; P=0.0002) and WOMAC (ß=-6.3, 95% CI -9.4 to -3.2; P=0.0003).
- At 24 months, responder rates were 86.5% with combination therapy versus 51.1% with ablation alone (P=0.0004); the authors call for randomized trials to confirm this.
Original abstract (PubMed)
BACKGROUND Cooled genicular radiofrequency ablation (CRFA) is used to treat symptomatic knee osteoarthritis (OA), although treatment response may decline over time. This study evaluated 24-month outcomes of CRFA alone versus CRFA combined with intra-articular botulinum toxin type A (BoNT-A). MATERIAL AND METHODS In this retrospective observational comparative-effectiveness cohort study, 90 patients with moderate-to-severe knee OA underwent CRFA alone (n = 50) or CRFA plus intra-articular BoNT-A (n=40). The combination group received BoNT-A at baseline and a planned repeat injection at ~12 months. Pain and function were assessed using the Numerical Rating Scale (NRS) and the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). The primary durability endpoint was the between-group difference in longitudinal NRS trajectories over 24 months, assessed using adjusted mixed-effects modeling. RESULTS Both groups demonstrated substantial early improvement; outcome trajectories diverged after ~12 months. Significant treatment-by-time interactions were observed for NRS (ß=-0.84, 95% confidence interval [CI] -1.21 to -0.47; P=0.0002) and WOMAC outcomes (ß=-6.3, 95% CI -9.4 to -3.2; P=0.0003). At 24 months, mean observed NRS scores were 4.2±2.3 after CRFA alone and 1.8±0.9 after CRFA plus BoNT-A; responder rates were 51.1% and 86.5%, respectively (P=0.0004). CONCLUSIONS In this retrospective observational cohort, a longitudinal treatment pathway combining CRFA with intra-articular BoNT-A was associated with more sustained pain relief and functional improvement over 24 months than CRFA alone. Prospective randomized studies are needed to confirm these findings and clarify the independent contributions of adjunctive and repeat intra-articular BoNT-A.
Earlier evidence / dates not confirmed
Includes older studies, year-only dates, and future-dated records. Inclusion does not imply landmark status.
- No matching papers in this section with the selected filters.
Ongoing registrations
From ClinicalTrials.govRegistrations, not results. These registry entries describe ongoing studies, not their findings. They are not counted as published evidence above; check linked records for updates and associated publications.